RA0590

antibody from Oursmab

Targeting: PDGFRA CD140a, GAS9, PDGFR2

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0590

Provider

Oursmab

Product name

Olaratumab (Biosimilar Reference Antibody) (PDGFRA)

Antibody type

Monoclonal

Description

Olaratumab is a fully human monoclonal antibody that targeted platelet-derived growth factor receptor alpha (PDGFR¦Á), a receptor tyrosine kinase involved in cell proliferation, migration, and stromal support. By binding to PDGFR¦Á, olaratumab blocked ligand (PDGF-AA, PDGF-BB, PDGF-CC) binding and receptor activation, thereby inhibiting downstream signaling pathways. It was granted accelerated approval in 2016 in combination with doxorubicin for the treatment of advanced soft tissue sarcoma (STS) in adults not amenable to curative treatment with radiotherapy or surgery, based on improved overall survival in a Phase II trial. However, subsequent Phase III trial (ANNOUNCE) failed to confirm survival benefit, leading to its voluntary withdrawal from the market in 2019.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.